TY - JOUR
T1 - The role of parental and grandparental epigenetic alterations in familial cancer risk
AU - Fleming, Jessica L.
AU - Huang, Tim H.M.
AU - Toland, Amanda Ewart
PY - 2008/11/15
Y1 - 2008/11/15
N2 - Epigenetic alterations of the genome such as DNA promoter methylation and chromatin remodeling play an important role in tumorigenesis. These modifications take place throughout development with subsequent events occurring later in adulthood. Recent studies, however, suggest that some epigenetic alterations that influence cancer risk are inherited through the germline from parent to child and are observed in multiple generations. Epigenetic changes may be inherited as Mendelian, non-Mendelian, or environmentally induced traits. Here, we will discuss Mendelian, non-Mendelian, and environmentally induced patterns of multigenerational epigenetic alterations as well as some possible mechanisms for how these events may be occurring.
AB - Epigenetic alterations of the genome such as DNA promoter methylation and chromatin remodeling play an important role in tumorigenesis. These modifications take place throughout development with subsequent events occurring later in adulthood. Recent studies, however, suggest that some epigenetic alterations that influence cancer risk are inherited through the germline from parent to child and are observed in multiple generations. Epigenetic changes may be inherited as Mendelian, non-Mendelian, or environmentally induced traits. Here, we will discuss Mendelian, non-Mendelian, and environmentally induced patterns of multigenerational epigenetic alterations as well as some possible mechanisms for how these events may be occurring.
UR - http://www.scopus.com/inward/record.url?scp=56449099478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56449099478&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-08-2184
DO - 10.1158/0008-5472.CAN-08-2184
M3 - Review article
C2 - 19010880
AN - SCOPUS:56449099478
SN - 0008-5472
VL - 68
SP - 9116
EP - 9121
JO - Cancer Research
JF - Cancer Research
IS - 22
ER -